Hesperos creates first organ-on-a-chip digital twin to predict drug responses, setting a new benchmark for New Approach ...

"We think we’re going to have major breakthroughs in the next few years to better treat the symptoms and try to slow the ...

About 90,000 people are diagnosed with Parkinson's disease (PD) each year—one person every six minutes. While most people ...

A wearable technology developed by Technion Professor Hossam Haick and colleagues in China enables real-time, noninvasive ...

OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress ...

OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has ...

Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...

A wearable technology developed by Technion Professor Hossam Haick and colleagues in China enables real-time, non-invasive tracking and optimized treatment for diabetic patients.

Q3 2025 Earnings Call Transcript July 14, 2025 Simulations Plus, Inc. beats earnings expectations. Reported EPS is $0.45, ...

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...

Medpace beats Q2 2025 earnings, raises FY guidance, showcasing strong biotech demand. Click here to read an analysis of MEDP ...